As per annexure enclosed
APOLLOHOSP · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.1 pts more than Nifty 100 and 3.2 pts more than its Hospital peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Apollo Hospitals reported strong FY2025-26 results. Standalone revenue grew 13.7% to Rs.93,262 million with PAT up 15.1% to Rs.14,926 million and EPS at Rs.103.81. Consolidated revenue rose 15.7% to Rs.252,285 million with PAT jumping 33% to Rs.20,027 million and EPS at Rs.135.04. The Board recommended a final dividend of Rs.10 per share (total dividend Rs.20 including interim). Key corporate actions include merger of Apollo Hospitals North Limited (wholly owned subsidiary), divestment of Apollo Specialty Hospitals and Apollo Fertility to Cloudnine for Rs.15,500 million, and re-appointment of Executive Chairman Dr. Prathap Reddy and Independent Director Ms. Rama Bijapurkar. Statutory auditors issued unmodified opinions. Credit ratings remain AAA/AA+.
Strong operational performance with 33% PAT growth on consolidated basis and positive corporate restructuring moves should support the stock. The Cloudnine transaction and subsidiary mergers indicate strategic portfolio optimization.